Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

It was five years ago this month that COVID-19 was beginning to consume the headlines. Around the world, those headlines provided an early view of what a pandemic might look like here in the U.S. In ...